Rallis India Ltd
NSE:RALLIS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
226.05
368.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Rallis India Ltd
Earnings Call Analysis
Q3-2024 Analysis
Rallis India Ltd
The quarter presented multifaceted challenges, ranging from a significant grain deficit in India to channel inventory issues causing degrowth in North America and Europe. Despite an atmosphere of unpredictability spurred by irregular monsoons and decreased sowing areas, the company managed to safeguard its growth and profitability amid declining prices for various general active ingredients and subdued demand in significant markets like Latin America.
Even with the external headwinds, the company delivered reassuring financials; revenue for the quarter reached INR 598 crores, alongside improvements in both EBITDA and PAT, which stood at INR 61 crores and INR 24 crores respectively. The margins showed an upward trend, with EBITDA margins at 10.2% and PAT margins at 3.8%.
The Domestic Crop Care business braved the storm of erratic climatic conditions, posting a 6% revenue growth by volume. Optimism takes root with the launch of three new products, adding to the 16 products released across several categories and markets during the nine-month period. Expanding the distribution network to about 5,000 distributors and increasing the retail footprint to roughly 62,000 outlets, the company is planting the seeds for flourishing growth despite fungicide liquidation being sluggish in areas like Maharashtra due to clear weather and reduced honey and crop sowing.
The company's international business was less of a wellspring and more of a tributary, with a significant 26% decline in exports. The export segment continues to face challenges, constrained by pricing pressures and inventory management. In light of these difficulties, the company is realigning its strategies, including liquidating some products at slimmer margins to prevent inventory issues, and benefitting from reduced costs alongside new product introductions like pendimethalin to maintain positive momentum.
Embarking on an ambitious journey of innovation and expansion, the company has doubled down on its commitment to research and development. It has commenced construction on an integrated R&D facility, envisioning a capital expenditure of about INR 150 crores for the year. This investment symbolizes the company's unswerving dedication to pioneering new products and technologies which fortify its market position.
Two of the company's products, Diggaz and Aatish Express, have shown remarkable growth. Diggaz doubled its reach from the previous fiscal by crossing about 4 lakh packets, and Aatish Express also witnessed substantial growth with 5.5 to 6 lakh packages compared to the previous year's 2.5 lakh packets. These breakout achievers underline the company's ability to innovate and capture market demand effectively.
You don't have any saved screeners yet
Ladies and gentlemen, good day, and welcome to Rallis India Limited's Q3 FY '24 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Gavin Desa from CDR India. Thank you, and over to you, sir.
Thank you, Michelle. Good day, everyone, and thank you for joining us on Rallis India Limited's 9 Months and Q3 FY '24 Earnings Conference Call. We have with us today Mr. Sanjiv Lal, the Managing Director and CEO; Mr. S. Nagarajan, the Chief Operating Officer; and Ms. Subhra Gourisaria, the Chief Financial Officer. Before we begin, I would like to mention that some of the statements made in today's discussion may be forward-looking in nature and involve risks and uncertainties. A detailed statement in this regard is available in the results presentation sent to you earlier. I now invite Mr. Sanjiv Lal now to open the proceedings of the call. Over to you, Sanjiv.
Thanks, Gavin, and good morning, everyone. As usual, I will start with a brief overview of the industry, after which, I will discuss the Rallis' specific developments. To start with, the industry grappled with numerous challenges in the initial half of this fiscal. India itself experienced a 6% grain deficit compared to historical average, posing difficulties beyond just the low precipitation, spatial distribution challenges also emerged. In particular, inadequate rainfall during kharif led to moisture deficit in the soil and reduced water storage in reservoirs.
The rabi season reflected a small decline in the sowing area compared to the corresponding period in the previous year. In addition to weather-related challenges, the industry struggled with the declining prices of various general active ingredients, primarily due to continued high inventory overhang.
On a global scale, challenges also emerged in Latin America, which is a substantial market for numerous Indian agrochemical companies, where demand remains subdued. North America and Europe faced degrowth issues attributed to channel inventory issues.
Moving on to value-specific developments. Our performance during the quarter is largely in line with what we have been guiding in our earlier calls. Volume growth for the quarter is positive, but because of steep cost inflation -- deflation, in fact, our price growth was negative at 8%, resulting in a revenue decline of 5%.
Our revenues for the quarter stood at INR 598 crores. EBITDA for the quarter stood at INR 61 crores against INR 53 crores during the corresponding period last year. PAT for the quarter stood at INR 24 crores against INR 22 crores with corresponding period last year. During the quarter, EBITDA and PAT margins improved to 10.2% and 3.8%, respectively, compared to Q3 of FY '23.
Moving on to the individual businesses, starting with Domestic Crop Care. As mentioned earlier, revenues have been impacted by the delayed and unpredictable monsoons. Our efforts in terms of calibrating placement with market agility and focused marketing helped in our 6% revenue growth during the quarter, supported by a 7% volume growth in Crop Care.
Regarding regional demand, North, Central and Southeast Asia have exhibited resilience. While West and Southwest India, particularly in Maharashtra and Karnataka have experienced subdued demand due to lingering effects of the deficit monsoon. Fungicide liquidation in Maharashtra has been sluggish, influenced by clear weather conditions and decline in honey and crop sowing.
Despite these problems, we remain focused towards enhancing our product mix, expanding our reach and deepening our connected customers. We launched 3 new products during the quarter for application in multiple crops. So far, during the first 9 months of the current financial year, we have introduced 16 products across various categories and markets. We are optimistic that these efforts will contribute to our growth in the years ahead.
Our distribution network for Domestic Crop Care business stood at close to about 5,000 distributors and our retail footprint has increased to about 62,000 as of end of December.
Moving to international business. Exports continue to witness challenge with 26% degrowth during the quarter. Demand in general remained muted across our key markets including the United States and Europe. Product prices are soft and channel inventories continue to remain high.
In terms of individual products, all our key products, pendi, metri, acephate and hexa witnessed approximate 15% to 30% price decline versus the previous year. Even in these turbulent times, pendimethalin is showing traction and we have announced expansion of capacity of pendimethalin to support the positive growth momentum.
Moving on to Contract Manufacturing. It continues to remain steady. As highlighted earlier, we have signed 3 contracts, one of them an intermediate, had already commenced in H1. During Q3, we dispatched a new technical from our multipurpose plant for one of the Japanese innovators and a new formulation for us -- from our plant in the chemical zone. We are optimistic that over time, we will be able to scale up our Contract Manufacturing business.
Our Seeds business, we experienced a positive first half, predominantly fueled by a strong performance of our common -- cotton hybrid, Diggaz. In addition to Diggaz, the new cotton hybrid, Aatish Express has gained traction in Maharashtra and the Southern cotton belt. Sales of other crops such as paddy, maize and millets have been steady.
Q3 being a small quarter. Our revenue was INR 32 crores. The distribution network for the Seeds business is now around 2,750 distributors and a retail footprint of about 47,000 retailers. While we have taken measures to enhance our rabi portfolio, we anticipate that the Seeds business will continue to be predominantly kharif oriented in the near term. Our actions towards improving the profitability of our business are progressing well.
In summary, although we anticipate ongoing challenges in the near term, especially in the exports business, we remain optimistic of the overall potential in the medium to long term. Actions around portfolio expansion through new product launches and expansion of distribution reach and market investments will continue to drive profitable growth.
We're also commencing the construction of our integrated R&D facility and expect it to be ready within 18 months. And this is also going to go a long way in building a steady product pipeline, in line with our long-term ambition. With these opening remarks, I will now request Subhra for an analysis of our financials. Subhra, over to you.
Thank you, Sanjiv. Good morning, everyone, and thank you for joining us today for our Q3 and 9 months earnings call. Let me quickly walk you through our financial performance for the quarter, post which we should commence the Q&A session.
Starting with the top line for the quarter, our revenue stood at INR 598 crores as against INR 630 crores generated during Q3 of FY '23, which is lower by 5%. Volume growth is positive, but pricing challenges have impacted the overall growth.
EBITDA for the quarter stood at INR 61 crores as against INR 53 crores during the corresponding period of last year. Margin for the quarter stood at 10% as against 8% during Q3 of last year. Our efforts around agile pricing, shorter pricing cost and shorter procurement has helped in improving gross contribution.
Further, our actions around timely liquidation, even at lower prices in the past have ensured we have mark-to-market for finished goods. Lower export mix, better domestic performance and overall cost control has helped in improving gross margin.
We also continue to be prudent in terms of overheads during these turbulent times. Profit for the quarter stood at INR 24 crores as against INR 22 crores during Q3 of last year.
Moving to business-wise performance. In the backdrop of challenging monsoon conditions and steep cost volatility, our actions have helped the domestic business growth at 6%. We continue to focus on the quality of sales and collections.
As far as the international business is concerned, overall situation remains challenging. Demand as well as pricing environment remains muted in turn, impacting the revenue and profitability of the business. Our focus will be to drive volume growth as much as possible and ensure best possible capacity utilization.
We are also happy with the commencement of dispatches to few new prominent global customers during the quarter. Our Contract Manufacturing business delivered steady performance during the quarter and remain positive on a long-term basis. And as far as Seeds is concerned, we've had a good year following the performance of a cotton hybrids, Diggaz and Aatish Express. Our efforts on working capital continues to progress well. Our inventory levels are significantly under control, especially in Seeds business. And we continue to remain cash positive during the quarter as well. On CapEx, we envisage that expense for this year will be in the range of INR 150 crores.
To conclude, I would like to iterate that we remain positive on the business on a medium- to long-term basis, basis our recent strategic initiatives coupled with the commissioning of the Dahej unit. That concludes the opening remarks. We can now commence the Q&A session.
[Operator Instructions] The first question is from the line of Prashant Biyani from Elara Securities.
Yes. Subhra ma'am, can you elaborate further on this agile pricing point? And how it is bearing fruit for you on the margin expansion side?
So Prashant, what I meant was that we are looking at the market context, and we are looking in with the business team on what is the pricing actions to be taken to remain competitive in the market. And as far as the international business is concerned, we have spoken in the past that even if we had to liquidate some of the products at a lower margin, we have done that to ensure that our inventory levels do not [indiscernible]. Both these actions, I would say, has helped us in ensuring our gross margins are protected.
But ma'am, I mean on the international front, liquidating at a lower price would drag your margin. But is it only because of your change in geography mix that we are seeing margin expansion? Or this dynamic pricing is helping you to increase margin in the domestic business? If this is true, then how is it doing it?
So our export margin are certainly under pressure. It's not that -- but overall, as a product and a portfolio level, we have been able to improve the margin.
I'll add, Subhra. So I think we have to distinguish between the international business and the domestic business. As far as the international business, what you're saying is absolutely correct. Our margins are actually lower, right, this quarter compared to the last year same quarter, Q3 of FY '24 versus Q3 of FY '23 for the reasons that are quite obvious, right, in terms of the price points falling much faster than the cost points.
As far as the domestic business is concerned, there is definitely an improvement in the margin. And that is happening because of a couple of factors: one, of course, is the overriding drop in costs, which is certainly facilitating the process. But I think in terms of pricing also, there is a lot of short calls that we have been taking in the last few months, particularly more in the last 6 months, I should say, and certainly in Q3 also.
What it means is that on a very short basis, like 10 days kind of basis, there is a very close monitoring of how the product prices are moving. So that has contributed. The second is, of course, our mix also has improved, I should say, in terms of the contribution margins. We have had some couple of new products that have got introduced, which you are already aware of. Last quarter, we had introduced Clasto, an insecticide, which has also been a good product from the point of view of margins as well.
So it's a combination of agile pricing, it's a combination of mix change in the domestic market, and, of course, cost -- raw material cost reductions as well. From the standpoint of DC level. And at the overall level, there is fixed cost control also that was mentioned earlier. That has also contributed to EBIT margin improvement.
And Prashant, also the mix, because the domestic business has mixed growth, better gross margin. At an overall portfolio level as well, the mix is positive. That's also contributed to improvement in gross margin.
Sure. And ma'am, lastly. Leaving aside this year, on us, is there a steady state margin for international business? Or it is quite volatile depending on the global Act Ing prices, leaving aside this year?
No, it's actually quite volatile, as we exactly said. It will depend on when the raw materials are sourced and where the purchase -- and it also differs between different products and the competitive context. But I think, we had mentioned earlier that considering that the overheads are low for this business at the EBITDA margin level, the business is comparable to domestic business in terms of margins in the longer term...
The next question is from the line of Tarang from Old Bridge Asset Management.
Just a couple of questions from my side. If I look at 9 months FY '24 or Q3 FY '24, your operating expenses have come off reasonably versus the base quarter, which is everything in conversion costs, except employee cost. So what are the key factors that have driven this? So that's one.
The second, in terms of your Seeds business, how are you guys placed to feed kharif of '24 in terms of maize, paddy and cotton. And do you have to have products for rabi corn?
On the fixed cost, there has been a special emphasis that we've been giving on managing our cost structures at manufacturing levels as well at as the sales, marketing and other corporate-related costs. That has certainly helped in maintaining -- managing the cost, I would say. And as far as the Seeds business is concerned, there have been challenges in hybrid seed production.
As far as cotton is concerned, I think we are largely in line with what we were expecting to produce for the upcoming kharif. And there is certain inventory that we are holding. So we still need to fully establish what is going to be the hybrid seed production from the current sowing season. So we've given an estimate of that. But yes, there is going to be a certain amount of pressure for the next year's kharif's placement.
Is it pervasive across crops? Are you talking only about cotton?
Cotton, largely, we are okay because whatever we were intending for next year, we've been able to secure the production for that.
Okay. So your comment was more for the other crops?
That's right. That's right, yes.
Okay. And are you present in corn, which is sown in rabi?
Present, but it's very small, yes.
Okay. And just last, if you could give us a sense on how much was Aatish in FY '24 versus, say, FY '23 and the years before because that product seems to be garnering a reasonable traction, and similar number for Diggaz?
[indiscernible]
Broad figures, yes, I can give you broadly. We have crossed about 4 lakh packets for Diggaz this year and about 5.5 to 6 lakh packages for Aatish Express this year. .
And how much was this in the previous period, previous year?
Diggaz was last year closer to 2 lakhs, 2.5 lakhs -- below 2.5 lakhs. So it's kind of a...
[indiscernible] Aatish.
Aatish was also 2.5 lakhs, 2.75 lakhs kind of reach.
Okay. So there's been a reasonable growth across both the products?
Yes, it's doubled in FY '24 over the previous year.
The next question is from the line of Ankur Periwal from Axis Capital.
First question on the export or the international pricing. You did mention that lower pricing has been putting the margin under pressure. I just wanted to see where -- or how much is the differential between our pricing versus, let's say, competition, which primarily is largely churning up. So pricing-wise competitiveness over there?
Well, I think, obviously, I think in the cases that we have been able to win the orders at an overall level, not just from the standpoint of competitiveness. We are based on pure price alone, but overall, in terms of service availability, quality, timely supply. Everything put together, we have been able to, obviously, be competitive. But if you just take broadly on a pricing basis, certainly, I think the prices from China are -- in cases -- in some cases, lower. But I think as you'll appreciate, it is also an important point about registrations and all of that, that is going into a decision by the customer. So I think we try to be fairly close to China. I can't say that we are lower than China. There are cases where China is definitely better than India and certainly our prices, too.
Sure. And just a follow-up. Basis, your understanding, is it that Chinese are selling it below the cost or maybe cost to cost?
Well, very difficult to say -- very difficult to -- I think their cost structure and all of that, on the price -- the drop in prices are, as you know, very, very steep, right? For the chemicals that we sell, we have mentioned that we actually have seen 15% to 30% drop over last year, the same quarter, Q3 of FY '23. So it's hard to say, but yes, it's possible.
Sure. And just second question on our strategy, which you highlighted the short cycle focus versus a long cycle one. Is it more specific for the domestic market and which is the large part of the cost cutting as well as the margin accretion happened? Or are you focusing on this strategy equally across the export as well as the domestic market?
Both the markets. See, I think if you look at it from the front-end pricing point of view, it is, of course, in both the markets. Because even in the international markets, the demand situation is fairly weak, right? It is still muted. So we are taking a short time. Even the customers would like to sort of keep it short. And domestic market, of course, we are doing that. From a procurement point of view also, we have shortened our cycles. We are actually taking near-term procurement calls. So that we are able to sort of navigate the cost points if the raw material prices were to further fall down.
That's it. And just if you can help me 9 months volume growth or degrowth for the Domestic Crop Care as well as the exports?
We tell you in a bit, Ankur.
Sure, Subhra madam. No worries.
The next question is from the line of Viraj from SiMPL.
Am I audible?
Yes.
Just 3 broader questions. First is on the domestic piece and the question is largely -- one is on the volume outperformance. So you've talked about having a positive volume growth. In an environment, the industry -- inventory is quite high and the season has not been [indiscernible]. So if you can just probably give more elaborate color in terms of other drivers of that growth to say a new product scale up? And how is the performance of the base business has been in Domestic Crop Care?
So in domestic, I think the volume growth is largely coming because of our insecticide category. That is, of course, related to the new products that we have launched. Benzilla, which was launched in this quarter and Clasto, which was launched the last quarter. Benzilla, of course, as you know, is for BPH control in paddy, and Clasto is for whitefly control in cotton and chili. These 2 have contributed significantly for the overall growth. We have had challenges on the fungicide front, as was also mentioned earlier. So there has been, I could say, a degrowth there. But overall, insecticide is what has driven the growth. Geographically, Andhra, Telangana, these locations have actually driven the growth, if you look at it for the last quarter.
A lot of these will be primarily placement driven, right, not consumption driven because most of -- the key season for this would be primarily kharif, maybe not that much rabi, especially if you sow cotton or [indiscernible]. So do you see a possibility of sales return kind of a situation going into Q2?
Well, I think the BPH product, Benzilla, BPH comes late in the crop life cycle for paddy. So it actually comes in the Q3, because in kharif of '23, the crop would have started, right? And then it would have reached maybe close to 80 or 90 days, depending on the market, 70 to 100 days kind of a time frame in Q3. So consumption has been happening there, liquidation. And we have also found that for cotton, it was almost kind of the tail end stages of Q3. So therefore, the amount of Clasto that has gone there is actually comparatively small. It's more in the chili crop which has actually been in this.
The next question is from the line of Eesha Mohanty from Kotak Securities.
My first question is on the impact on the revenues because of the freight rate disruption? And the second question is what sort of revenue could be expected from the new Contract Manufacturing products in the upcoming years?
Let's see, I think the impact has been more from the standpoint of higher freight costs. Definitely, I think that is impacting us. And we do have sales there in the European and around that Mediterranean Sea region, which was dependent on the Suez Canal. So there is an impact consequent to that. And the second question was -- sorry, Eesha, if you can repeat it, please?
What sort of revenue can we expect from the new Contract Manufacturing products in the upcoming years?
Yes. So Eesha, what we have mentioned is that our new opportunities in contract manufacturing, these are smaller opportunities. So this will take time to scale up. So what we are currently trying to do is to add more and more products and customers in our Contract Manufacturing business. So there will be a number of small, small opportunities that we will be building on. It will take some time to scale because some of them are very new products in the market. So it takes some time to scale.
The next question is from the line of Bhavya Gandhi from Dalal & Broacha Stock Broking.
You mentioned about...
Your voice is not clear. You are still breaking. Maybe return to use your handset...
Is it better? Is it better?
Yes, sir, please continue.
Yes. You mentioned that price erosion was closer to -- 30%. So if you can just name key molecules...
Sir, it's still breaking, actually. We are not able to hear you clearly.
Is it better?
Yes, sir, please continue.
Okay. [indiscernible] So if you can just name key molecules and the price erosion over there? That will be really helpful.
So I think this is the general overall range for all the molecules. Specific [indiscernible], as you know, there is published information that is available, it can be accessed, but this is broadly the kind of range for our portfolio. Yes.
No. I mean if you can name any key molecules and their prices 1 year back and what is the price right now?
Well, not readily available. So that's why I was saying that this is the range. We can share it with you later. But I'll also look at that if it's available.
Perfect. Okay. Okay. And also just wanted to know, I mean, what was the current quarter international versus domestic mix and for 9 months as well?
So current quarter versus international would be, domestic to international be broadly 2:1. So 65% would be coming from international business and...
[indiscernible]
65%. And on a year-on-year basis, it's -- yes, [indiscernible].
30% to 32% will be international [indiscernible] on the lower side this year.
Perfect. Got it. And just 1 last question. In history, have you seen this kind of scenario where channel inventory has been to this level? And how long did this cycle last historically? I mean, if yes, then -- I mean, is it like a 2-, 3-year cycle? Or is this like a 4-, 5-quarter cycle? Because I'm seeing all our agrochemical companies, they are forwarding their guidance maybe by 1, 2, 3 quarters now. So if you can just elaborate on that front? Historically, what has been the outlook?
Historic, I don't think...
We don't have that kind of information, historic, but it has happened in the past also. But of course, the reasons and the contributory factors would have been very different at that point in time. I think 2013 or '15 or something. It is available. I mean this kind of information is also available. No, we are not able to readily offer it to you. The drivers were different at that point in time. Now the drivers are, of course, quite different. How long it will stretch? We certainly think that this quarter is something where we have very good visibility, and it is not ending in a hurry in this quarter. Now we will have to see how quickly in the next financial year it will revise. Whether it is going to be Q1 or Q2, it's a little bit hard to say at this point in time.
[Operator Instructions] The next question is from the line of S. Ramesh from Nirmal Bang Equities.
So you see the trend in gross margins and EBITDA margins, what would be the difference in terms of the EBITDA margin or the absolute EBITDA between the international business and the domestic business? And you can give us the share of the international revenues in 3Q or 9 months, that will be very useful?
I think we gave you the share already, that it was broadly 65% for our domestic business. As far as the EBITDA margin is concerned, and I'll talk more about the steady state. The steady-state international business will make lesser gross margin, but at EBITDA margin, both the businesses would be broadly similar.
Pardon me, I didn't hear the last part.
It would be similar.
So you are saying the international business is still profitable, although currently 15% to 30% decline in the prices, right?
I'm not talking about this quarter. But on a longer-term basis -- and yes, the international business is certainly profitable even for this quarter on a gross margin basis.
Yes, it is.
And overhead turn is very high if you take the exclusive.
So if you take this -- and assuming normalized inventory levels and normalized procurement and placement, do we see the domestic and international margins kind of reach parity? And to that extent, can we expect your overall growth in earnings and cash flows show a positive trajectory, say, over the next 2 years? And to that extent, can we expect the ROCE to show an improvement in the next 2, 3 years?
Yes. I think certainly, as Subhra is mentioning, on a steady-state basis, as the EBITDA margin level, the international business will be more or less in line with the domestic business.
Okay. Sir, just 1 last short on the contract business. So when do you see the Contract Manufacturing business reaches a material share in terms of the overall revenue, say, 5%, 10%? And is that going to be similar in terms of the margin and ROCE profile? Or would you be able to reach a certain critical mass where the margin and return profile in the Contract Manufacturing would be higher than your existing Crop Care business because if you see the contract manufacturing companies across India and other countries, the margins tend to be a little bit higher. So what is your overall sense of the business building?
That is true. Contract manufacturing does have better margins than what we call catalog sales. And what is positive is that one of the businesses of ours, which is a polymer business, which has been almost dormant for quite a period of time, is now slowly coming back. So that will also help in sort of improving the percentage of our business coming from exports. So we see the Contract Manufacturing business steadily grow over the next 2, 3 years because some new products have also been introduced for catalog sales in the exports business apart from contract manufacturing opportunities, which we've already mentioned.
The next question is from the line of Rohit Nagraj from Centrum Broking.
Congrats on good set of numbers. First question is on CapEx. So I believe, including the FY '24 CapEx, we will be completing the INR 800 crores that we had planned a few years ago. How much of this is currently reflected in terms of revenues -- or rather not exactly revenues, but maybe from a utilization perspective, just to get an understanding that this capacity will be available for the next 2 years or 2.5 years or so? And just a number, what would be the CapEx run rate from FY '25 onwards?
Ladies and gentlemen, the management line has been disconnected. Kindly stay connected. I'll be trying to reconnect them.
[Technical Difficulty]
Ladies and gentlemen, thank you for patiently holding. The management line has been reconnected. Sir, should I ask the participant to...
No, no. I was answering Rohit's question, I would just complete that. So in terms of the big ticket items, we had the formulation facility, the chemical zone. So that is very good in terms of its utilization, the multipurpose plant, which is the other big ticket investment of ours. We are expecting about a 60% capacity utilization next year as we add more products to it. And, of course, we've also got a number of capacity enhancements for our existing products. Most of them have already been operationalized.
The next big ticket investment is the work which we are starting on the new R&D center, that will be spread out over the next 15 to 18 months in terms of expenditure. So largely, we are outlooking about INR 150-odd crores for the current financial year. And maybe next year, it will be about INR 170-odd crores.
Sure. That helps. So second question is on the pendi. So what is the current competitive scenario? And what gives us confidence of putting up the incremental facility, when in China, we have been seeing that there have been capacity enhancements across all the generics?
I think for us, we have a good customer list with us and our business has been quite steady with our existing customers. Price drops alone not withstanding all those issues. But certainly, we see that there's an opportunity for us to further add capacity. So that we are able to support our customers in the key markets. In fact, what has also happened is that -- we have also got the Europe registration for pendimethalin, so that is giving us another direct market.
The next question is from the line of Vishnu Kumar A.S. from Avendus Spark.
Just on the Contract Manufacturing business, you highlighted that we would see some growth from here on. Is that business a fixed margin? Or will we see some volatility if the prices go up and down?
So typically, for our Contract Manufacturing, the way we're structuring the contracts are with key raw material costs being passed through. So in a way it is supporting the level of margin that we will be getting from these contracts. Does that answer your question?
Yes.
Yes. I'm just saying that the key is starting the deals will pass through costs.
Okay. So irrespective of the Chinese assuming the prices continue to be soft, we will at least get the fixed margin per kilo exported. Would that be a right understanding? .
That will be a correct understanding. But we are having a pass-through for the key raw materials, yes.
Understood. What level of growth can we expect? I mean, even if you can give some sense into the next couple of years on this side of the business? If you could help us on that?
See, one is, as I mentioned that one of our key products, which is polymer, is coming back. So that itself, we should see it getting back towards historical levels over the next 2, 3 years. Our new business opportunities are going to be small ticket opportunities, and we are quite happy to support new customers with even small volumes. The purpose of our multipurpose plant is to give that flexibility to be able to meet customer needs. So I would not want to hesitate a percentage of growth, but I would certainly say that we should be well placed to add at least 2 new customers, products over the next 3 years.
Got it, sir. And one final, if I may. The reservoirs are not great. And also, we are hearing that the snowfall in the North has not been -- I mean, at least in the upper regions of Himalayas has not been good. Do we expect that the upcoming season for kharif will be a bit more challenging? And any sense that you could give us, at least on this side? If these 2 conditions are there in the past, things have not been great, good. Any sense on that?
So Vishnu, actually, if that goes with the kind of information that is currently available, it is certainly not going to be very easy. To start with, there is lower reservoir levels, so it's already impacting what's happening in rabi. That is one. Second is that if you look at the El Nino forecast, the probability of El Nino continuing into next year is almost at 75% probability. So some of these things -- as of now, given we said that it may not be so straightforward. We'll have to wait for some guidance coming from IND and others, but this is what the current information.
The next question is from the line of Darshita Shah from Antique Stock Broking.
I just had 1 question regarding the tax rate during the quarter. What was the reason behind it being lower? And is it sustainable in nature?
Darshita, the tax rate is dependent on, of course, how the income tax and, to say, tax profit is calculated, which takes into consideration income tax depreciation and others. And that is where there is some difference when you're comparing year-on-year. So I wouldn't be able to say whether it will continue or it will not continue. But as you can, for all practical purposes, consider the margin at that such for your working.
The next question is from the line of Sneha from SKS Capital.
I just wanted to ask what would be the impact or if there is any logistics or shipping cost increase because of the Red Sea situation?
Shipping cost for -- your question is shipping cost impact because of the Red Sea situation?
Yes.
Maybe a few tens of cents. Okay?
The situation, I would say dynamic, and we'll have to see how this impact the overall costing.
Okay. And secondly, the destocking of the inventory, what is the current situation? And have we improved that? I mean, is the outlook going forward is better?
At this point in time, it still seems to be highly stocked. There are some products where we -- for example, the imports that are coming into the U.S. market are looking a little better than what they were 1 year back, right? November, December '23 versus November, December '22. But I think it is too early to say across the board, and it is too early to say across all markets. So we do expect as far as this quarter is concerned, like we mentioned a little earlier, things are not looking like it is going to be addressed. Now how quickly it will get addressed in the next financial year, is what we are now trying to see. Whether it is going to be Q1, late Q1 or early Q2 or in Q2.
The next question is from the line of Sandeep Abhange from LKP Securities.
Yes. Firstly, I had a question related to...
Sir, your audio -- may we request you to kindly speak a little bit louder.
Hello. Can you hear me?
Okay, sir. This is fine.
I have a question related to your Seeds business. So your Seeds business has been higher by 33% during this quarter. And so just wanted to know what drove this sales? And overall, I just wanted to know the outlook for 2024 for the -- for your Seeds business, particularly.
So this quarter is a very small quarter. INR 32 crores and INR 24 crores were the last year figure. So that 1/3, what we're talking about, increase, I would suggest that we should look at it over a longer, like a YTD kind of a basis. On a YTD basis, what has driven a larger revenue this year, like we mentioned earlier, has been our performance on Diggaz and in Aatish. I wouldn't put too much of -- I wouldn't set too much store by the Q3 33% growth.
As far as next year is concerned, I think like what was mentioned earlier, certainly, we are having challenges this year in terms of the seed production. We are in the midst of the production season. So we will have to really see where we close on maize and paddy, not on cotton, but maize and paddy in terms of production levels. And therefore, after you add up the inventory levels that we are already carrying, where we might end on the supply levels for next year. So maybe we'll have some better clarity a few -- maybe a few weeks down the line.
The next question is from the line of Anik Mitra from Finnomics Solution.
Okay. Sir, my first question is related to the late monsoon which is evident for last 2, 3 years continuous basis. So what strategy you were adapting? And you also rightly mentioned about 75% probability of El Nino this year. So what strategy you are adopting considering late monsoon in this year as well?
Yes. So one of the things that have actually contributed to the success of many of the hybrids that we have in the market from a seed point of view, has been the shorter duration of that, whether you take Diggaz or even Aatish. So I think one of the important things is to try and make sure we have enough short-duration products on the seed side. As far as the crop care, crop protection business is concerned, I think it is a challenge because you go with the assumption that things might be normal, and then you end up placing certain stocks and then you have some difficulty later on. So what we are trying to do is to try and get as much information as close to the placement as possible. And there, our deployment of the integrated business planning tool, the digitalization efforts that we are undertaking, it's just started this year. We are hoping that it will have some meaningful benefit in terms of helping us to predict the kind of demand that might be there in the market. It's early days, but that is what we are doing. And of course, to have a portfolio which can actually address if there are any changes in circumstances rather than just focusing on 1 or 2 products, which could get disrupted if things change adversely for those products. So those are the things that we are doing.
Fair enough, sir. Sir, my next question is related to a few products. Like do you see any price erosion in acephate, pendimethalin, metribuzin, PEKK, if you can throw some light in the international market point of view and as well as in the domestic market?
Yes. In fact, that is what we mentioned, right? All the products that we are having in our portfolio, pendimethalin, metribuzin, all those products which you mentioned, we have seen price erosion between 15% to 30% compared to the last year same time.
This is in the Indian market, right, sir?
No, in the international market. These are in the international. And the cost also has gone down. So these are price reductions, but there's also cost reductions which has happened in the international market.
[Operator Instructions] The next question is from the line of Tarang from Old Bridge Asset Management.
Just a question on the Crop Care business, the technicals business. Acephate, pendi, Hexaconazole, metribuzin. These are some of your key products. You seem to have reasonable local scale in these products. So you would have a sense on peer set cost structures, whether it's in India and China. And some of these products or maybe most of these products are also seeded by Chinese players. We have seen in the last 6 to 8 months, where in case of other products, the market pricing has been onerous enough for the technical prices to be -- maybe at par or maybe in some cases, even lower than the variable cost of production because of the aggression that some of the peers have demonstrated. Has it been true in your set of products?
On an average basis, we are not seen a negative contribution, if you can call it like that. We are not in that kind of situation.
But you have seen it happening across other molecules?
Just to also add, for example, if we are seeing significant price erosion where we feel that it is not even covering our cost of manufacturing, we simply don't produce that material. We don't be sitting on inventory in a market which is uncertain. For example, just to let you know that metribuzin is one such products that we've been having significant challenges because: one is the inventory is high, plus the price is low. So we prefer to keep the asset idle rather than to produce and hold on price inventory. Likewise, even for acephate, we've seen a very, very sharp decline in sales, especially from key markets like Brazil. And there again, there are no buyers; even at any price, there are no buyers. So there, again, we had to take slight production cuts so that we won't land up sitting with the wrong inventory.
Yes. And that is what we -- actually, when we talked about ability earlier, I mean, I think it is across multiple dimensions. Pricing is one part of it, but also in procurement and in production also. Basically, the supply chain as well. So yes -- no, we haven't been in that kind of situation.
Got it. Would it be possible for you to hazard a guess that the players are supplying at the current prices in all the markets that you also play in? Would you be able to comment further in your view, at the prices currently versus something like an acephate or metribuzin. Are those players making any profits?
Hard to say. I think some of them are based in China. Also, for example, for acephate, there are producers in China. It's very hard to really say what their cost structure is. Yes, but I think, let's put it this way, I think if you push for an answer, yes, the possibility exists that there could be negative GCs, right? Negative GCs. Possibility exists, but we don't know for sure.
We'll take the next question from the line of Viraj from SiMPL.
Two questions. First is just continuing with the question from the earlier participant. To put it in a different way, are you seeing any signs of capacity adjustments, say, in China or India for the products which we -- the major products which we cater to?
Are you saying -- sorry, capacity adjustments. So you are saying...
Any perspective on demand -- so demand side, give a fair color that the end markets are not doing that great and saying U.S. or Europe or LatAm, even current season has not been great. But on the supply side, are you seeing any signs of capacity closure or shutdowns, both in India and China for the major products which we cater to?
So it is -- again, you see -- I think definitely, I think 2023 has been a very difficult year, and we have heard situations where smaller players have had deep troubles in terms of being able to make their ends meet because the prices have got so depressed, maybe they are sitting on high cost inventory themselves in terms of raw material, making it very difficult for them to hold on. If they produce, they end up with losses, produce themselves. If they don't, they are ending up with high capital being locked up in inventory, right? So there are these kind of things that we hear. But explicitly for the products that we are operating with us some capacities working its way out of the market, whether it is for acephate or pendi. No, we have not heard -- metribuzin -- no, we have not heard about that.
So any further increase in capacity or new addition, any?
Capacity additions have also been obviously affected, right, because everybody has -- at least in the customer conversations that we have, have indicated that everybody is really focused on dealing with the current inventory overhang that is there at an overall level. And certainly, for the products that we are having, also we have not heard somebody has added capacity, let's say, in the last 6 months to 9 months.
Okay. Second question is on the gross margin part, right? So if you kind of reported financials, we saw a little over 300 basis points expansion in gross margin. And if we look at the [ bonus fees ], the margin expansion could be well over 500 basis points, right, year-on-year. Now question is that you highlighted that there are 3 reasons for the margin expansion. But if you were to just understand the major factor among 3, the RM part, the dynamic pricing and the new product . What is the larger factor driving the margin expansion? And how does dynamic pricing really aid in margin expansion? If you can, please, elaborate more on that.
So Viraj, when we are talking about dynamic pricing, if you recall, we had also said that we are going to be taking shorter pricing calls for procurement of materials, procurement calls, right? So if we are very clear as to what price we are able to procure some of the key actives, we know how to price it. And we are not sitting on higher cost inventory which is forcing us to price it at a level which we will be losing sales. So that is, I think, what has contributed. Basically, taking shorter procurement calls will help us in the dynamic pricing.
As a process to -- just to sort of give a little bit more clarity for you as a process, for example, when we are buying some stuff, it is -- along with the procurement team, we also have a marketing person embedded in that process, so that there is actually an integrated view we are able to take about the overall end-to-end, how the whole thing will play out from a margin, from a volume point of view. It is a more inclusive or more collective kind of process, decision process and that allows us to take better calls.
The next question is from the line of Gandhi from Dalal & Broacha Stock Broking.
Just 1 question on the contract manufacturing side. Just wanted to know, is it like a long-term agreement? Or do we have any minimum offtake guaranteed? Or if you can throw some light on the same?
So for our older contracts, these are, in a way, long-term only, it's not that we have a fixed price for a long period. But yes, there is a long-term commitment to each other from our customer and from us. For some of the newer opportunities, since some of these products are new products, these are still on the basis of shorter contracts. They're not long-term contracts. But I guess, once the product becomes successful in the market, they will convert into longer-term contracts.
Okay. And are you the sole supplier for this? Or are there other suppliers also for this produces?
At least for one of the molecules that we are currently doing for the Japanese innovator, we are the only one.
Okay. Got it. And is there any minimum offtake guaranteed to you at least?
No, as I mentioned that we are supporting them with establishing the product, and we also need them to succeed for the volumes to build up for us. So we have tied up into long-term contracts.
Okay. And on the process front, we don't do any innovation, right? I mean, on the process front, it's only contract manufacturing, right? [indiscernible] manufacturing, if I'm not wrong.
No, no. As it turns out for this particular products, there has been a lot of work that has been done in our labs by our team and the customer has been [indiscernible] by the work that our team has done.
Ladies and gentlemen, that was the last question. I would now like to hand the conference over to the management for closing comments. Over to you, sir.
Thank you. And I hope we'll be able to provide clarity on your questions. For us, Q4 is a smaller quarter, and our larger focus will be on planning for the upcoming kharif that we talked about, some of the potential challenges on the seed side, especially in terms of availability for the next few season, but we are just working through that. We expect international business, which has been another problematic area for the last 3 quarters, we expect this to pick up momentum only towards end of Q1 all going well. But as one of the participants in today's call mentioned that new guidances keep coming in terms of when things will start normalizing. So we're also hopeful that maybe Q1, Q2 it will start normalizing. And inventory destocking is taking more time than what we had thought about because if you recall, we were actually expecting things to turn around by Q4, which is not really happening.
We will continue to pursue all efforts to drive maximum utilization of our plants and get volume-led growth, the price possibly coming under pressure. Margins will remain a priority, and we will continue to improve on an annualized basis through better product mix and pricing actions, which we talked about.
Our recent initiatives positioned us well l to capitalize on the growth opportunities in both domestic and international markets, and we further focus on improving collection, that is going to be an important area for us. Investments that we have made over the last couple of years in R&D, product development, manufacturing and capabilities will enable us to drive our growth agenda in a sustainable way. Our long-term strategy of driving competitive growth remains on track, and we will keep reviewing all opportunities as relevant. Thank you all very much for joining until we meet next quarter ending. Thank you.
Thank you, members of the management. Ladies and gentlemen, on behalf of Rallis India Limited, that concludes this conference. We thank you for joining us, and you may now disconnect your lines. Thank you.